Menu
Search
|

Menu

Close
X

Co-Diagnostics Inc CODX.OQ (NASDAQ Stock Exchange Capital Market)

1.06 USD
-0.02 (-1.85%)
As of 4:00 PM EDT
Previous Close 1.08
Open 1.09
Volume 3,691
3m Avg Volume 174,583
Today’s High 1.09
Today’s Low 1.06
52 Week High 3.77
52 Week Low 0.70
Shares Outstanding (mil) 17.02
Market Capitalization (mil) 22.29
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.085
FY18
-0.501
FY17
-0.612
FY16
-0.195
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
663.02
7.90
Price to Book (MRQ)
vs sector
4.01
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
-143.46
12.69
Return on Equity (TTM)
vs sector
-155.73
17.13

EXECUTIVE LEADERSHIP

Dwight Egan
Chairman of the Board, President, Chief Executive Officer, Since 2013
Salary: $23,750.00
Bonus: --
Reed Benson
Chief Financial Officer, Secretary, Since 2017
Salary: --
Bonus: --
Brent Satterfield
Chief Scientific Officer, Since 2019
Salary: $81,096.00
Bonus: --
Eugene Durenard
Independent Director, Since 2019
Salary: --
Bonus: --
Edward Murphy
Independent Director, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4049 S Highland Dr
SALT LAKE CITY   UT   84124-1664

Phone: +1801.2789769

Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

SPONSORED STORIES